The global inhalation CDMO market was valued at USD 4.32 billion in 2025. The market is estimated at USD 4.81 billion in 2026 and is expected to reach USD 12.03 billion by 2036, growing at a CAGR of 9.6% from 2026 to 2036. This report assesses the propellant transition, low global warming potential (GWP) filling capacity, reformulation and regulatory workloads, generic bioequivalence requirements, the value chain, pricing, competition, and future growth opportunities.
The market includes outsourced development, testing, and production of drugs given by inhalation or through the nose, in pressurized metered dose inhalers (pMDIs), dry powder inhalers (DPIs) of capsule, blister, and reservoir types, nebulizer products including blow-fill-seal unit doses, nasal sprays and powders, and soft mist and other novel inhalers. Services range from formulation, device design, and drug-device integration to aerodynamic testing, bioequivalence studies, clinical supplies, commercial filling, and regulatory support. Because an inhaled product works as a single drug-device system and few drug companies have kept this expertise in-house, outsourcing in inhalation runs well ahead of oral solid dose.
Under Regulation (EU) 2024/573 on fluorinated greenhouse gases, metered dose inhalers enter the hydrofluorocarbon quota system for the first time, with 2025-2026 quotas based on past inhaler share, phased integration between 2027 and 2030, and, according to the regulation, alignment with a cut of about 85% below baseline by 2030, so every pMDI must switch to a lower-GWP propellant. Contract supply of these new propellants is already proven at scale: Bespak's Holmes Chapel site in the U.K. became the first CDMO to produce a pMDI commercially with HFO-1234ze, a propellant with near-zero GWP. AptarGroup reported only 1% core sales growth in the second quarter of 2026, which shows that respiratory device volumes are rising slowly and that growth here comes mainly from transition work and complexity.
Providers must fund low-GWP lines, containment, and validation before customers have completed their own reformulation and refiling plans, on a timetable fixed by regulators rather than by demand. Transition revenue is also finite, as development and regulatory work stops once a portfolio is converted, which raises the risk of surplus capacity in the later forecast years. Generic inhalers face slow, costly bioequivalence programs covering device performance, in vitro aerodynamics, and often clinical endpoints, so originator brands keep their position long after patent expiry. Propellants, valves, canisters, and blister laminates come from a few vendors, and any registered component needs requalification before it can be swapped.
Multi-year programs to reformulate and refile whole inhaler portfolios are the largest opportunity, followed by qualified low-GWP commercial filling, where providers with free capacity can choose their programs. Systemic and central nervous system nasal products, often sponsored by specialty and emerging companies that outsource from feasibility to launch, bring higher value per program and demand that lasts beyond the transition. Inhaled biologics and peptides on dry powder platforms form a longer-term opportunity. Key trends include a shift in value from filling toward development, analytical, and regulatory work, the merging of device and drug capability within single providers, and the creation of focused inhalation companies, such as the April 2024 spin-out of Bespak Group from Recipharm.
By dosage form, the inhalation CDMO market is segmented into pressurized metered dose inhalers, dry powder inhalers (DPIs: capsule-based, blister-based, and multi-dose reservoir), nebulizer solutions & suspensions, nasal sprays & nasal powders, and soft mist & novel inhalers. Pressurized metered dose inhalers are expected to account for the largest share in 2026, as a large installed base of presentations must be reformulated for new propellants, each one needs development, testing, bridging, and regulatory work, and qualified low-GWP filling sits with only a few contract organizations. Nasal sprays & nasal powders are expected to grow at the highest CAGR, as nasal delivery moves into systemic and central nervous system uses, these programs carry higher development value, and their demand does not rely on the propellant change.
By service, the inhalation CDMO market is segmented into commercial manufacturing & filling, formulation & product development, device development & drug-device integration, analytical & bioequivalence testing, clinical trial supply, and regulatory support. Commercial manufacturing & filling is expected to account for the largest share in 2026, given the unit volumes and multi-year terms of supply contracts and the higher value of filling compared with earlier project work. Formulation & product development is expected to grow at the highest CAGR, as each affected inhaler must be reformulated before a commercial batch is made, with supporting characterization, clinical bridging, and a regulatory variation for every authorization. Testing and regulatory services should also grow quickly, as this work precedes filling.
By molecule type, the inhalation CDMO market is segmented into small molecules, biologics & peptides, and other molecule types. Small molecules are expected to account for the largest share in 2026, because corticosteroids, long-acting beta agonists, and muscarinic antagonists make up almost all commercial inhaled volume and because propellant transition work centers on these products. Biologics & peptides are expected to grow at the highest CAGR, driven by inhaled proteins and peptides for respiratory and systemic use, the need for spray drying and particle engineering that keep molecules intact, and the few providers able to pair this work with dry powder device design.
By therapeutic area, the inhalation CDMO market is segmented into asthma, chronic obstructive pulmonary disease, allergic rhinitis & nasal congestion, central nervous system & systemic nasal, cystic fibrosis & rare respiratory, pulmonary infection, and other therapeutic areas. Asthma is expected to account for the largest share in 2026, supported by a large treated population, heavy use of pMDIs in asthma care, and the wide range of reliever, preventer, and combination products that need reformulation. Central nervous system & systemic nasal is expected to grow at the highest CAGR, as nasal products are developed for rapid-onset uses such as rescue medicines and migraine therapies, these programs carry higher value, and specialty and emerging sponsors outsource them in full. COPD remains a large segment, with AptarGroup naming asthma and COPD therapies among its prescription growth drivers.
By customer type, the inhalation CDMO market is segmented into large pharmaceutical companies, specialty & mid-size pharmaceutical companies, emerging biotechnology companies, and generic & value-added manufacturers. Large pharmaceutical companies are expected to account for the largest share in 2026, as they own the respiratory portfolios that need reformulation, contract large commercial volumes, and sell each product in many presentations and markets. Emerging biotechnology companies are expected to grow at the highest CAGR, since they have no in-house formulation, device, or manufacturing capability, outsource completely, and hold many of the inhaled biologics, peptide, and systemic nasal programs. Generic & value-added manufacturers should grow more slowly, held back by the cost of proving bioequivalence for inhaled products.
Europe is expected to hold the largest share of the global inhalation CDMO market in 2026, as inhaler development and production skills are concentrated in the U.K., Germany, Italy, Switzerland, and the Nordic countries, the EU F-gas rules that drive the transition apply there, and the region hosts providers such as Bespak, Lonza, Nemera, Recipharm, and Vectura. Much of the new transition capacity is also European, including the HFA-152a filling lines announced by Bespak and Kindeva Drug Delivery's expanded Loughborough site, with Kindeva having received U.K. government grant funding to support low-GWP propellant commercialization. North America holds a significant share, backed by a large respiratory prescription market, many emerging biotech sponsors, and providers such as Catalent, Kindeva Drug Delivery, Thermo Fisher Scientific, and PCI Pharma Services.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, driven by India's large inhaled respiratory manufacturing base, including export-focused contract supply by Cipla and Glenmark Pharmaceuticals, rising respiratory treatment rates, lower assembly and filling costs, and the gradual adoption of propellant rules in regional frameworks. The Rest of the World holds a limited share, focused on regional supply and specialist production.
The inhalation CDMO market is more concentrated than contract manufacturing overall, because only a few organizations can develop and fill inhaled drug-device products at commercial scale. Providers compete on qualified filling capacity, propellant know-how, drug-device integration, testing depth, regulatory and inspection records, speed, and the ability to manage a product from early feasibility to launch within one quality system. Leaders are qualifying low-GWP lines, adding formulation and regulatory staff, and building dry powder and nasal positions that will outlast the transition. Notable developments include the first commercial-scale CDMO production of a pMDI with HFO-1234ze at Holmes Chapel, Bespak's separation from Recipharm in April 2024, and U.K. grant funding for Kindeva's transition capacity.
Key companies profiled in the report include Bespak Group (U.K.), Kindeva Drug Delivery (U.S.), Recipharm AB (Sweden), Catalent, Inc. (U.S.), Aptar Pharma (AptarGroup, Inc.) (U.S.), Nemera (France), H&T Presspart (U.K.), Lonza Group AG (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Vectura Group Limited (U.K.), Merxin Ltd. (U.K.), Aurena Laboratories AB (Sweden), Renaissance Lakewood, LLC (U.S.), PCI Pharma Services (U.S.), Cipla Limited (India), and Glenmark Pharmaceuticals Limited (India).
The market includes outsourced development, testing, and production of drugs given by inhalation or through the nose, in pressurized metered dose inhalers (pMDIs), dry powder inhalers (DPIs) of capsule, blister, and reservoir types, nebulizer products including blow-fill-seal unit doses, nasal sprays and powders, and soft mist and other novel inhalers. Services range from formulation, device design, and drug-device integration to aerodynamic testing, bioequivalence studies, clinical supplies, commercial filling, and regulatory support. Because an inhaled product works as a single drug-device system and few drug companies have kept this expertise in-house, outsourcing in inhalation runs well ahead of oral solid dose.
Under Regulation (EU) 2024/573 on fluorinated greenhouse gases, metered dose inhalers enter the hydrofluorocarbon quota system for the first time, with 2025-2026 quotas based on past inhaler share, phased integration between 2027 and 2030, and, according to the regulation, alignment with a cut of about 85% below baseline by 2030, so every pMDI must switch to a lower-GWP propellant. Contract supply of these new propellants is already proven at scale: Bespak's Holmes Chapel site in the U.K. became the first CDMO to produce a pMDI commercially with HFO-1234ze, a propellant with near-zero GWP. AptarGroup reported only 1% core sales growth in the second quarter of 2026, which shows that respiratory device volumes are rising slowly and that growth here comes mainly from transition work and complexity.
Market Dynamics
The propellant transition is the main driver of the inhalation CDMO market, because a new propellant changes solubility, suspension stability, vapor pressure, spray plume, and device fit, so each reformulated inhaler becomes a new development program that needs bridging studies, stability data, performance testing, and a Type IA, IB, or II variation in every market. Commercial lines able to fill HFO-1234ze and HFA-152a are scarce, since they need modified equipment, flammability containment for HFA-152a, and qualification for each product, which supports pricing for the few holders. Demand also comes from complex drug-device products and from nasal delivery for systemic and central nervous system uses, where AptarGroup reported a growing systemic nasal pipeline in the first quarter of 2026.Providers must fund low-GWP lines, containment, and validation before customers have completed their own reformulation and refiling plans, on a timetable fixed by regulators rather than by demand. Transition revenue is also finite, as development and regulatory work stops once a portfolio is converted, which raises the risk of surplus capacity in the later forecast years. Generic inhalers face slow, costly bioequivalence programs covering device performance, in vitro aerodynamics, and often clinical endpoints, so originator brands keep their position long after patent expiry. Propellants, valves, canisters, and blister laminates come from a few vendors, and any registered component needs requalification before it can be swapped.
Multi-year programs to reformulate and refile whole inhaler portfolios are the largest opportunity, followed by qualified low-GWP commercial filling, where providers with free capacity can choose their programs. Systemic and central nervous system nasal products, often sponsored by specialty and emerging companies that outsource from feasibility to launch, bring higher value per program and demand that lasts beyond the transition. Inhaled biologics and peptides on dry powder platforms form a longer-term opportunity. Key trends include a shift in value from filling toward development, analytical, and regulatory work, the merging of device and drug capability within single providers, and the creation of focused inhalation companies, such as the April 2024 spin-out of Bespak Group from Recipharm.
Segment Analysis
The report analyzes the market by dosage form, service, molecule type, therapeutic area, customer type, and geography, helping stakeholders identify the most attractive areas for investment, capacity, and partnering.By dosage form, the inhalation CDMO market is segmented into pressurized metered dose inhalers, dry powder inhalers (DPIs: capsule-based, blister-based, and multi-dose reservoir), nebulizer solutions & suspensions, nasal sprays & nasal powders, and soft mist & novel inhalers. Pressurized metered dose inhalers are expected to account for the largest share in 2026, as a large installed base of presentations must be reformulated for new propellants, each one needs development, testing, bridging, and regulatory work, and qualified low-GWP filling sits with only a few contract organizations. Nasal sprays & nasal powders are expected to grow at the highest CAGR, as nasal delivery moves into systemic and central nervous system uses, these programs carry higher development value, and their demand does not rely on the propellant change.
By service, the inhalation CDMO market is segmented into commercial manufacturing & filling, formulation & product development, device development & drug-device integration, analytical & bioequivalence testing, clinical trial supply, and regulatory support. Commercial manufacturing & filling is expected to account for the largest share in 2026, given the unit volumes and multi-year terms of supply contracts and the higher value of filling compared with earlier project work. Formulation & product development is expected to grow at the highest CAGR, as each affected inhaler must be reformulated before a commercial batch is made, with supporting characterization, clinical bridging, and a regulatory variation for every authorization. Testing and regulatory services should also grow quickly, as this work precedes filling.
By molecule type, the inhalation CDMO market is segmented into small molecules, biologics & peptides, and other molecule types. Small molecules are expected to account for the largest share in 2026, because corticosteroids, long-acting beta agonists, and muscarinic antagonists make up almost all commercial inhaled volume and because propellant transition work centers on these products. Biologics & peptides are expected to grow at the highest CAGR, driven by inhaled proteins and peptides for respiratory and systemic use, the need for spray drying and particle engineering that keep molecules intact, and the few providers able to pair this work with dry powder device design.
By therapeutic area, the inhalation CDMO market is segmented into asthma, chronic obstructive pulmonary disease, allergic rhinitis & nasal congestion, central nervous system & systemic nasal, cystic fibrosis & rare respiratory, pulmonary infection, and other therapeutic areas. Asthma is expected to account for the largest share in 2026, supported by a large treated population, heavy use of pMDIs in asthma care, and the wide range of reliever, preventer, and combination products that need reformulation. Central nervous system & systemic nasal is expected to grow at the highest CAGR, as nasal products are developed for rapid-onset uses such as rescue medicines and migraine therapies, these programs carry higher value, and specialty and emerging sponsors outsource them in full. COPD remains a large segment, with AptarGroup naming asthma and COPD therapies among its prescription growth drivers.
By customer type, the inhalation CDMO market is segmented into large pharmaceutical companies, specialty & mid-size pharmaceutical companies, emerging biotechnology companies, and generic & value-added manufacturers. Large pharmaceutical companies are expected to account for the largest share in 2026, as they own the respiratory portfolios that need reformulation, contract large commercial volumes, and sell each product in many presentations and markets. Emerging biotechnology companies are expected to grow at the highest CAGR, since they have no in-house formulation, device, or manufacturing capability, outsource completely, and hold many of the inhaled biologics, peptide, and systemic nasal programs. Generic & value-added manufacturers should grow more slowly, held back by the cost of proving bioequivalence for inhaled products.
Regional Analysis
The report covers four regions, Europe, North America, Asia-Pacific, and Rest of the World, with country-level analysis of 14 countries and rest-of-Europe and rest-of-Asia-Pacific groups. The regional analysis of the inhalation CDMO market considers filling capacity, propellant regulation, respiratory demand, sponsor activity, and cost.Europe is expected to hold the largest share of the global inhalation CDMO market in 2026, as inhaler development and production skills are concentrated in the U.K., Germany, Italy, Switzerland, and the Nordic countries, the EU F-gas rules that drive the transition apply there, and the region hosts providers such as Bespak, Lonza, Nemera, Recipharm, and Vectura. Much of the new transition capacity is also European, including the HFA-152a filling lines announced by Bespak and Kindeva Drug Delivery's expanded Loughborough site, with Kindeva having received U.K. government grant funding to support low-GWP propellant commercialization. North America holds a significant share, backed by a large respiratory prescription market, many emerging biotech sponsors, and providers such as Catalent, Kindeva Drug Delivery, Thermo Fisher Scientific, and PCI Pharma Services.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, driven by India's large inhaled respiratory manufacturing base, including export-focused contract supply by Cipla and Glenmark Pharmaceuticals, rising respiratory treatment rates, lower assembly and filling costs, and the gradual adoption of propellant rules in regional frameworks. The Rest of the World holds a limited share, focused on regional supply and specialist production.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard (market leaders, market differentiators, vanguards, and emerging players), and market share/rank analysis by key player for 2025. Company profiles include business overviews, financial overviews, inhalation service portfolios, capacity and propellant capability, manufacturing footprints, strategic developments, and SWOT analyses.The inhalation CDMO market is more concentrated than contract manufacturing overall, because only a few organizations can develop and fill inhaled drug-device products at commercial scale. Providers compete on qualified filling capacity, propellant know-how, drug-device integration, testing depth, regulatory and inspection records, speed, and the ability to manage a product from early feasibility to launch within one quality system. Leaders are qualifying low-GWP lines, adding formulation and regulatory staff, and building dry powder and nasal positions that will outlast the transition. Notable developments include the first commercial-scale CDMO production of a pMDI with HFO-1234ze at Holmes Chapel, Bespak's separation from Recipharm in April 2024, and U.K. grant funding for Kindeva's transition capacity.
Key companies profiled in the report include Bespak Group (U.K.), Kindeva Drug Delivery (U.S.), Recipharm AB (Sweden), Catalent, Inc. (U.S.), Aptar Pharma (AptarGroup, Inc.) (U.S.), Nemera (France), H&T Presspart (U.K.), Lonza Group AG (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Vectura Group Limited (U.K.), Merxin Ltd. (U.K.), Aurena Laboratories AB (Sweden), Renaissance Lakewood, LLC (U.S.), PCI Pharma Services (U.S.), Cipla Limited (India), and Glenmark Pharmaceuticals Limited (India).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global inhalation CDMO market.
- Explains how Regulation (EU) 2024/573 and the move to low-GWP propellants create reformulation, testing, regulatory, and filling work for contract providers.
- Assesses low-GWP filling capacity, reformulation cost and timelines, and the risk of overcapacity once transition work ends.
- Identifies high-growth opportunities across dosage form, service, molecule type, therapeutic area, customer type, and region.
- Tracks growth areas beyond the transition, including systemic and central nervous system nasal delivery and inhaled biologics and peptides.
- Benchmarks leading providers on capacity, propellant capability, drug-device integration, manufacturing footprint, and strategic developments.
- Supports capacity investment, partner selection, outsourcing strategy, and market entry decisions for CDMOs, device suppliers, pharmaceutical companies, and investors.
Key Questions Answered
- How big is the global inhalation CDMO market today, and how will it grow through 2036?
- How does the EU F-gas regulation change the workload for pMDI reformulation, testing, and refiling?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How scarce is commercial-scale filling capacity for HFO-1234ze and HFA-152a, and who holds it?
- Which dosage forms, services, molecule types, therapeutic areas, and customer types will grow the fastest?
- How will systemic nasal delivery and inhaled biologics sustain demand after the propellant transition?
- How do bioequivalence requirements affect generic inhaled product development?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies, and how are they positioned on capacity, capability, and partnerships?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Inhalation CDMO Market, by Dosage Form
6. Inhalation CDMO Market, by Service
7. Inhalation CDMO Market, by Molecule Type
8. Inhalation CDMO Market, by Therapeutic Area
9. Inhalation CDMO Market, by Customer Type
10. Inhalation CDMO Market, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Bespak Group
- Kindeva Drug Delivery
- Recipharm AB
- Catalent, Inc.
- Aptar Pharma
- Nemera
- H&T Presspart
- Lonza Group AG
- Thermo Fisher Scientific Inc.
- Vectura Group Limited
- Merxin Ltd.
- Aurena Laboratories AB
- Renaissance Lakewood, LLC
- PCI Pharma Services
- Cipla Limited
- Glenmark Pharmaceuticals Limited
